Recent Progress on Topical Drug Therapy for Corneal Neovascularization
ChemMedChem · 2025-11-28 · 20 (23)
DOI: 10.1002/cmdc.202500366 ↗At a glance
Übersichtsarbeit in ChemMedChem, published online on 2025-10-16. Written by Xin-Can Huang and 5 co-authors. Institution: Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Hongkou District, Sha…. Major MEDLINE topics: Corneal Neovascularization, Angiogenesis Inhibitors. Cited 4 times so far (Crossref); 123 references. Funded by: National Natural Science Foundation of China.
Abstract (original language)
The cornea is a crucial refractive medium in the visual system, characterized by its avascular and transparent nature under physiological conditions. Pathological factors such as ocular trauma and inflammation can induce the formation of new capillaries from the limbal vascular network, leading to corneal neovascularization (CNV). With an associated blindness rate as high as 12%, CNV has become a significant challenge in ophthalmology. Current treatment strategies for CNV primarily include drug therapy such as anti‐inflammatory and antiangiogenic agents, as well as surgical procedures like laser photocoagulation. These approaches are often limited by invasive procedures, suboptimal efficacy, and other constraints. Therefore, developing effective, safe, and convenient therapeutic options has become a critical research focus. Due to structural barriers of the ocular surface, the bioavailability of conventional eye drops is limited to ≈1%–5%, significantly restricting therapeutic efficacy. In recent years, researchers have been actively optimizing drug delivery systems using nanotechnology, hydrogels, and other advanced techniques to prolong ocular surface retention time, improve corneal penetration, and enhance drug release properties. This review summarizes recent advances in topical drug therapy for CNV, focusing on its pathogenesis, therapeutic agents, and delivery strategies, as well as approaches to enhance the bioavailability of topical treatments.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Hongkou District, Shanghai, 200080, China.
- CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 10019…
Funding
- National Natural Science Foundation of China
Cite
APA
Huang, X. C., Xu, G. Y., Yang, P. P., Wang, L., Wang, H., & Hu, Y. (2025). Recent Progress on Topical Drug Therapy for Corneal Neovascularization. ChemMedChem, 20(23). https://doi.org/10.1002/cmdc.202500366
Vancouver
Huang XC, Xu GY, Yang PP, Wang L, Wang H, Hu Y. Recent Progress on Topical Drug Therapy for Corneal Neovascularization. ChemMedChem. 2025;20(23). doi:10.1002/cmdc.202500366
BibTeX
@article{Huang2025,
author = {Huang, Xin-Can and Xu, Guo-Yang and Yang, Pei-Pei and Wang, Lei and Wang, Hao and Hu, Ying},
title = {Recent Progress on Topical Drug Therapy for Corneal Neovascularization},
journal = {ChemMedChem},
year = {2025},
volume = {20},
number = {23},
doi = {10.1002/cmdc.202500366}
}
EUVIMED